Alon Kushnir, RedDress CEO
Chronic wound biotech raises $26M in Series D to expand blood clot products
Wound care company RedDress, whose products heal chronic wounds using the patient’s own blood, has raised $26 million in a Series D funding round. The plan is to use the money to expand use of its tech in the US, enter more global partnerships and move into other conditions.
This latest round of funding brings the Israel-based company’s total haul to $43 million. CEO Alon Kushnir told Endpoint News that they’ve been able to attract investors because RedDress’s products, ActiGraft and ActiGraft+, have already been cleared by the FDA, commercialized and come with robust data behind them.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters